Morse Asset Management Inc Grows Position in AbbVie Inc. $ABBV

Key Points

• Morse Asset Management boosted its AbbVie stake by 89.6% in Q3, ending the period with 13,268 shares worth about $3.07 million.
• Several large institutions also increased positions — e.g., Wellington jumped 457.4% to ~10.54M shares and Vanguard holds ~177.3M shares — leaving institutional ownership at 70.23%.
• AbbVie beat quarterly EPS estimates ($2.71 vs. $2.65) with revenue up 10%, issued FY2026 guidance of 14.37–14.57 EPS, and declared a quarterly dividend of $1.73 (annual $6.92) for a 3.1% yield

Morse Asset Management Inc lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 89.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,268 shares of the company's stock after acquiring an additional 6,270 shares during the period. Morse Asset Management Inc's holdings in AbbVie were worth $3,072,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of AbbVie in the second quarter valued at about $4,288,200,000. Wellington Management Group LLP grew its holdings in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the last quarter. Laurel Wealth Advisors LLC grew its holdings in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company's stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. increased its position in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in AbbVie by 169.3% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company's stock valued at $876,662,000 after acquiring an additional 2,969,202 shares during the period. Hedge funds and other institutional investors own 70.23% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ABBV shares. HSBC raised AbbVie from a "hold" rating to a "buy" rating and increased their price objective for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Morgan Stanley upped their price target on AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Piper Sandler increased their price target on AbbVie from $289.00 to $299.00 and gave the stock an "overweight" rating in a report on Wednesday, February 18th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. Finally, Citigroup dropped their price objective on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $253.15.

AbbVie Price Performance

ABBV opened at $221.54 on Tuesday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market capitalization of $391.72 billion, a P/E ratio of 93.87, a P/E/G ratio of 0.76 and a beta of 0.34. The business has a 50 day simple moving average of $224.35 and a 200-day simple moving average of $224.89.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie's dividend payout ratio is 293.22%.

Insider Transactions at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.